Neutralizing activity to SARS‐CoV‐2 in 1.2 to 10.0 month convalescent plasma samples of COVID‐19: A transversal surrogate in vitro study performed in Quito‐Ecuador

Boris Villacrés‐Granda; Elius Paz; María José Burbano; Irina Villacrés‐Granda; Daniela Armijos; Mauricio Aguirre

doi:10.1002/jmv.27866

Neutralizing activity to SARS‐CoV‐2 in 1.2 to 10.0 month convalescent plasma samples of COVID‐19: A transversal surrogate in vitro study performed in Quito‐Ecuador

Journal

Journal of Medical Virology

ISSN

1096-9071

Date Issued

2022-05-26

Author(s)

Boris Villacrés‐Granda

Elius Paz

Universidad UTE

María José Burbano

Irina Villacrés‐Granda

Daniela Armijos

Mauricio Aguirre

DOI

10.1002/jmv.27866

URL

https://cris.ute.edu.ec/handle/123456789/453

Abstract

AbstractCoronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, was first reported in Wuhan, China, in December 2019. Diagnostic methods for the detection of the virus and seroconversion of neutralizing antibodies (NAbs) in plasma have been developed specifically, but some of them require a BSL3 facility. In this study, we used the SARS‐CoV‐2 Surrogate Virus Neutralization Test Kit to determine the presence or absence of NAbs anti‐receptor binding domain of the viral spike (S) glycoprotein in a BSL2 facility. The sample population was chosen in Quito, Ecuador, with a total of 88 COVID‐19 positive convalescent patients. We determined that 97.7% of the analyzed convalescent sera maintained the presence of NAbs with neutralizing activity, and this activity remained until 10 months after the infection in some cases. In addition, the relationship between the presence of NAbs and immunoglobulin G was significant compared to immunoglobulin M, which tended to be absent over time.